BridgeBio Oncology adds independent director Lebowitz

BridgeBio Oncology Therapeutics, Inc. reported that its board expanded to nine directors and appointed Peter Lebowitz, M.D., Ph.D. as a Class I director effective March 24, 2026.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported that its board expanded to nine directors and appointed Peter Lebowitz, M.D., Ph.D. as a Class I director effective March 24, 2026. His term runs until the 2026 annual stockholders meeting and he will serve on the nominating and governance and compensation committees.

The board determined Dr. Lebowitz is independent under Nasdaq and applicable regulations and disclosed no related-party arrangements or transactions requiring Regulation S-K Item 404(a) disclosure. As a non-employee director, he will receive standard board compensation, including a one-time stock option for 63,350 common shares at an exercise price of $8.72 per share, matching the Nasdaq Global Market closing price on March 24, 2026. He also entered into the company’s standard indemnification agreement covering certain expenses and liabilities arising from his board service.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did BridgeBio Oncology Therapeutics (BBOT) announce in its board structure?

BridgeBio Oncology Therapeutics expanded its board of directors from eight to nine members and appointed Peter Lebowitz, M.D., Ph.D., to fill the new vacancy. He will serve as a Class I director until the 2026 annual stockholders meeting and continue until a successor is qualified.

Who is Peter Lebowitz and what roles will he hold at BridgeBio Oncology Therapeutics (BBOT)?

Peter Lebowitz, M.D., Ph.D., has been appointed as a Class I director of BridgeBio Oncology Therapeutics. He will also serve on the Nominating and Corporate Governance Committee and the Compensation Committee, starting March 24, 2026, providing oversight on governance practices and executive and director compensation matters.

Is Peter Lebowitz considered an independent director at BridgeBio Oncology Therapeutics (BBOT)?

Yes. The board determined that Peter Lebowitz qualifies as an independent director under Nasdaq Stock Market rules and other applicable laws and regulations. The filing also states there are no arrangements, understandings, or related-party transactions requiring disclosure in connection with his appointment to the board.

What equity compensation will Peter Lebowitz receive from BridgeBio Oncology Therapeutics (BBOT)?

Peter Lebowitz will receive a one-time nonqualified stock option to purchase 63,350 shares of BridgeBio Oncology Therapeutics common stock. The exercise price is $8.72 per share, equal to the Nasdaq Global Market closing price on March 24, 2026, the effective date of his appointment.

How will Peter Lebowitz otherwise be compensated as a director of BridgeBio Oncology Therapeutics (BBOT)?

Beyond the option grant, Peter Lebowitz will receive cash and any additional equity compensation under the company’s amended and restated non-employee director compensation policy. That policy, previously filed with the SEC, governs standard fees for board and committee service for non-employee directors.

What indemnification protections does BridgeBio Oncology Therapeutics (BBOT) provide to Peter Lebowitz?

In connection with his appointment, Peter Lebowitz entered the company’s standard indemnification agreement. BridgeBio Oncology Therapeutics may indemnify him for certain expenses, including attorneys’ fees, judgments, fines, and settlement amounts reasonably incurred in actions arising from his service as a board member.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 04:52 PM Learn about SEC filing dates

false 0001869105 0001869105 2026-03-24 2026-03-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 24, 2026

BridgeBio Oncology Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41955		39-3690783
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

256 E. Grand Avenue, Suite 104

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 405-4770

(Telephone number, including area code, of agent for service)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		BBOT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Director Appointment

On March 24, 2026, the board of directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) increased the size of the Board to nine (9) directors and, upon the recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”) appointed Peter Lebowitz, M.D., Ph.D. as a member of the Board, with immediate effect to fill the vacancy created by the increase in Board size. Dr. Lebowitz will serve as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Dr. Lebowitz was appointed to serve on the NCG Committee and on the Compensation Committee of the Board, effective as of the date of his appointment as a director. The Board has determined that Dr. Lebowitz is “independent” as contemplated by the Nasdaq Stock Market and other governing laws and applicable regulations.

There are no arrangements or understandings between Dr. Lebowitz and any other persons pursuant to which he was appointed as director. There are no transactions in which Dr. Lebowitz has an interest requiring disclosure under Item 404(a) of Regulation S-K of the Securities Act of 1933, as amended.

Dr. Lebowitz will receive compensation for his services as a non-employee director and for any committee service in accordance with the Company’s amended and restated non-employee director compensation policy, a copy of which was filed as Exhibit 10.25 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2026, including the automatic grant of a one-time nonqualified stock option under the Company’s 2025 Stock Option and Incentive Plan to purchase 63,350 shares of the Company’s common stock, $0.0001 par value per share at an exercise price per share equal to $8.72 per share, the closing price on the Nasdaq Global Market on March 24, 2026, the effective date of his appointment to the Board.

In connection with his appointment, Mr. Lebowitz entered into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.26 to the Company’s Current Report on Form 8-K filed with the SEC on August 13, 2025. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Mr. Lebowitz for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts actually and reasonably incurred by him in any action or proceeding arising out of his service as a member of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
Date: March 26, 2026				By:		/s/ Eli Wallace
						Name: Eli Wallace Title: Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB